Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study

Edeler, David; Arlt, Sören; Petković, Vladana; Ludwig, Gerd; Drača, Dijana; Maksimović‐Ivanić, Danijela; Mijatović, Sanja; Kaluđerović, Goran N.

doi:10.1016/j.jinorgbio.2017.12.011

Cited by 15 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,[34][35][36][37][38][39][40] As a highlight, one of such compounds, namely TLD-1433 from the McFarland group, has now entered clinical trial as a PDT photosensitiser to treat bladder cancer 41 . However, to the best of our knowledge, there are only a few reports on the use of ruthenium compounds with therapeutic properties supported onto mesoporous silica, 42,43 which have been synthesised using a very similar approach to the one that we published in 2009 10,12 and have been tested in terms of regular cytotoxicity. Additionally, some other more advanced cytotoxic systems based on silica have also been reported.…”

Section: -29mentioning

confidence: 99%

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

et al. 2019

View full text Add to dashboard Cite

A series of nanomaterials based on mesoporous silica have been synthesised and functionalised with a photoactive polypyridyl ruthenium(ii) complex, namely [Ru(bipy)2-dppz-7-hydroxymethyl][PF6]2 (bipy = 2,2'-bipyridine, dppz = dipyrido[3,2-a:2',3'-c]phenazine), by various methods. The functionalisation reactions were based on the covalent binding to different ligands attached to the pores of the mesoporous nanoparticles and a simple physisorption using polyamino-functionalised mesoporous silica nanoparticles. The resulting nanostructured systems have been characterised by XRD, XRF, BET, SEM and TEM, observing the incorporation of the metallodrug onto the nanostructured silica in a different way depending on the synthetic method used in the loading reactions. In our studies, we have also observed that functionalisation with the metallodrug causes changes in the structural and textural features of the materials. The phototherapeutic activity of the ruthenium-functionalised materials in HeLa cervical cancer cells has been tested and the preliminary results are presented herein.

show abstract

Section: -29mentioning

confidence: 99%

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Thus, in order to avoid solvolysis of metal complexes various delivery systems such as mentioned above formulations loaded with these complexes have been currently proposed. Concluding, justification of application of drug delivery systems for highly active anticancer compounds lies not only in prevention of hydrolysis or solvolysis, but also in precise accumulation in the target tumor tissue, drug release, and selective local application [8]. Accordingly to all above-mentioned and due to poor solubility of studied ruthenium(II)…”

Section: Polymeric Micellesmentioning

confidence: 99%

“…On the other hand, RAPTA-C exhibits low in vitro activity, while being active in vivo, inhibiting lung metastases in mice [6]. Furthermore, combination of two or even more multifunctional structural elements brings into play different properties of a compound and may result in improving the spectrum of biological activity, novel mechanisms of action, and modification of the pharmacokinetic profile of the drug [7,8]. For instance, piano-stool Ru(II) compounds containing phosphines derived from fluoroquinolones can be prominent examples of this popular strategy of combining the structural elements, adopted currently in the design of new therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Polymeric micelle-mediated delivery of half-sandwich ruthenium(II) complexes with phosphanes derived from fluoroloquinolones for lung adenocarcinoma treatment

Kołoczek

Skórska-Stania

Cierniak

et al. 2018

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Novel half-sandwich ruthenium(II) complexes with aminomethyl(diphenyl)phosphine derived from fluoroloquinolones (RuPCp, RuPSf, RuPLm, RuPNr) were being investigated as alternatives to well-established metal-based chemotherapeutics. All compounds were characterized by elemental analysis, selected spectroscopic methods (i.e., absorption and fluorescence spectroscopies, ESI-MS, NMR, circular dichroizm), X-ray diffractometry, ICP-MS, and electrochemical techniques. To overcome low solubility, serious side effects connected with systemic cytotoxicity of ruthenium complexes, and acquiring the resistance of cancer cells, polymeric nanoformulations based on Pluronic P-123 micelles loaded with selected Ru(II) complexes were prepared and characterized. Resulting micelles (RuPCp_M, RuPNr_M) enabled efficient drug accumulation inside human lung adenocarcinoma (A549 tumor cell line), proved by confocal microscopy and ICP-MS analysis, allowing cytotoxic action. Studied complexes exhibited promising cytotoxicity in vitro with IC50 values significantly lower than the reference drug - cisplatin. The fluorescence spectroscopic data (CT-DNA titration, in vitro cell staining) together with analysis of DNA fragmentation (pBR322 plasmid, comet assay) provided clear evidence for the interaction with DNA inducing apoptotic cell death.

show abstract

“…Considering that most of the studied systems do not bear any potential targeting molecule to detect and potentiate the active and selective transport of the therapeutic species to the cancer cell line, an enhanced permeability and retention (EPR) effect was considered to be responsible for their slight selectivity towards cancer cell lines (in comparison with normal cell lines) [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. Nevertheless, very recent reports have studied the possibility of including a folate fragment for a more effective targeting of cancer cells, which has been partially achieved both in vitro [ 33 ] and in vivo [ 34 ] when using organotin(IV)-functionalized mesoporous silica nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

Role of Folic Acid in the Therapeutic Action of Nanostructured Porous Silica Functionalized with Organotin(IV) Compounds against Different Cancer Cell Lines

et al. 2020

View full text Add to dashboard Cite

The synthesis, characterization and cytotoxic activity against different cancer cell lines of various mesoporous silica-based materials containing folate targeting moieties and a cytotoxic fragment based on a triphenyltin(IV) derivative have been studied. Two different mesoporous nanostructured silica systems have been used: firstly, micronic silica particles of the MSU-2 type and, secondly, mesoporous silica nanoparticles (MSNs) of about 80 nm. Both series of materials have been characterized by different methods, such as powder X-ray diffraction, X-ray fluorescence, absorption spectroscopy and microscopy. In addition, these systems have been tested against four different cancer cell lines, namely, OVCAR-3, DLD-1, A2780 and A431, in order to observe if the size of the silica-based systems and the quantity of incorporated folic acid influence their cytotoxic action. The results show that the materials are more active when the quantity of folic acid is higher, especially in those cells that overexpress folate receptors such as OVCAR-3 and DLD-1. In addition, the study of the potential modulation of the soluble folate receptor alpha (FOLR1) by treatment with the synthesized materials has been carried out using OVCAR-3, DLD-1, A2780 and A431 tumour cell lines. The results show that a relatively high concentration of folic acid functionalization of the nanostructured silica together with the incorporation of the cytotoxic tin fragment leads to an increase in the quantity of the soluble FOLR1 secreted by the tumour cells. In addition, the studies reported here show that this increase of the soluble FOLR1 occurs presumably by cutting the glycosyl-phosphatidylinositol anchor of membrane FR-α and by the release of intracellular FR-α. This study validates the potential use of a combination of mesoporous silica materials co-functionalized with folate targeting molecules and an organotin(IV) drug as a strategy for the therapeutic treatment of several cancer cells overexpressing folate receptors.

show abstract

Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study

Cited by 15 publications

References 52 publications

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

Polymeric micelle-mediated delivery of half-sandwich ruthenium(II) complexes with phosphanes derived from fluoroloquinolones for lung adenocarcinoma treatment

Role of Folic Acid in the Therapeutic Action of Nanostructured Porous Silica Functionalized with Organotin(IV) Compounds against Different Cancer Cell Lines

Contact Info

Product

Resources

About